Table 1.
Preliminary results of main clinical trials with GSK2857916 (Belantamab Mafodotin).
| TRIAL NAME | NCT Number | PHASE | Number of Patients (Treatment Arm) | Previous Lines of Treatment (Median) | Previous Drugs | Combinatio n with Other Drugs | Efficacy | Aes (Grade 3–4) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| BMA117159 | NCT02064387 | I | 35 (part 2) | 1–≥10 | IMIDs PIs Alkilators |
/ | ORR 60% Median PFS 12 Months |
Corneal Events (9%), Thrombocytopenia (26%), Anaemia (14%) |
Trudel S, Blood Cancer Journal (2019) 9:37 |
| DREAMM-2 | NCT03525678 | II | 196 | 3–21 (7) | IMIDs PIs Anti-CD38 |
/ | ORR: 31% (2.5 mg/kg), 34% (3.4 mg/kg)Median PFS: 2.8 (2.5 mg/kg), 3.9 Months (3.4 mg/kg) | Kerathopathy (27% and 21%) Thrombocytopenia (20% and 33%) Anemia (20% And 25%) |
Lonial S, Lancet Oncol 2020; 21:207–221 |
| DREAMM-4 | NCT03848845 | I/II | 13 (part 1) | 3–13 (7.5)–2.5 mg/kg cohort 3–8 (5)–3.4 mg/kg cohort |
IMIDs PIs Anti-CD38 |
Pembrolizumab | ORR: 67% (2.5 mg/kg Cohort), 14% (3.4 mg/kg Cohort) | Kerathopathy (33% and 57%) | Nooka AJ, EHA2020, Abs EP955 |
Abbreviations: IMIDs, immunomodulatory drugs; PIs, proteasome inhibitors; ORR, overall response rate; PFS, progression-free survival